NEW YORK, Nov. 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update. "ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.
